Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 5/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ATP4A | P20648 | 1/20 | 0.37 |
| ▸ | ATP4B | P51164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283061 | 0.89 | AGER (0.42) | AGERACHEHTTKDM4EDRD2 | |
| SCHEMBL1283004 | 0.78 | ACHE (0.55) | AGERACHEHTTKDM4EDRD2 | |
| SCHEMBL1615010 | 0.75 | ACHE (0.43) | AGERACHEHTTKDM4EDRD2 | |
| SCHEMBL3445367 | 0.69 | KDM4E (0.68) | AGERKCNH2KDM4EHRH3 | |
| SCHEMBL1283165 | 0.69 | ACHE (0.55) | AGERACHEKDM4EATP4AATP4B | |
| SCHEMBL1283426 | 0.69 | ACHE (0.55) | AGERACHEKDM4EATP4AATP4B | |
| SCHEMBL1283485 | 0.69 | GCGR (0.44) | AGERACHEKDM4EHRH3 | |
| SCHEMBL1283564 | 0.68 | DRD3 (0.50) | AGERDRD2DRD3ATP4AATP4B | |
| SCHEMBL14417419 | 0.68 | SMN1; SMN2 (0.46) | AGERHTTKCNH2DRD2DRD3 | |
| SCHEMBL1283017 | 0.68 | SMN1; SMN2 (0.47) | AGERHTTKDM4EDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | AGER 1/4885ACHE 1301/4885HTT 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.